Cancer progress and priorities: Uterine cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 27, Issue 9, 2018, Pages 985-994

  Felix, Ashley S ^a   Brinton, Louise A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; TAMOXIFEN;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONTRACEPTIVE BEHAVIOR; FAMILY HISTORY; FEMALE; FUTUROLOGY; HEALTH DISPARITY; HEREDITY; HORMONAL THERAPY; HUMAN; MENOPAUSE; PREDICTION; PRIORITY JOURNAL; REPRODUCTIVE BEHAVIOR; RISK FACTOR; SEDENTARY LIFESTYLE; UTERUS CANCER; DISEASE EXACERBATION; PATHOLOGY;

DISEASE PROGRESSION; FEMALE; HUMANS; RISK FACTORS; UTERINE NEOPLASMS;

EID: 85053052903     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-18-0264     Document Type: Article

References (118)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. [cited 2018 Apr 7]. Available from: http://globocan.iarc.fr/Default.aspx. Lyon, France: International Agency for Research on Cancer. 2013.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.
4. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 2017; 26: 444-57.
5. Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B. Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol 2013; 37: 374-7.
6. Weiderpass E, Antoine J, Bray FI, Oh JK, Arbyn M. Trends in corpus uteri cancer mortality in member states of the European Union. Eur J Cancer 2014; 50: 1675-84.
7. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-21.
8. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1: S105-43.
9. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252-71.
10. Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008; 198: 218e1-6.
11. Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, et al. Surgical-pathological findings in type 1 and 2 endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol 2017; 145: 519-25.
12. Wright JD, Fiorelli J, Schiff PB, Burke WM, Kansler AL, Cohen CJ, et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 2009; 115: 1276-85.
13. Farley J, Risinger JI, Rose GS, Maxwell GL. Racial disparities in blacks with gynecologic cancers. Cancer 2007; 110: 234-43.
14. Allard JE, Maxwell GL. Race disparities between black and white women in the incidence, treatment, and prognosis ofendometrial cancer. Cancer Control 2009; 16: 53-6.
15. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol Oncol 2013; 130: 652-9.
16. Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Gynecologic cancer disparities: areport from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecol Oncol 2014; 133: 353-61.
17. Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev 2015; 24: 1407-15.
18. Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 2013; 22: 233-41.
19. Cote ML, Alhajj T, Ruterbusch JJ, Bernstein L, Brinton LA, Blot WJ, et al. Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Causes Control 2015; 26: 287-96.
20. Morris AM, Rhoads KF, Stain SC, Birkmeyer JD. Understanding racial disparities in cancer treatment and outcomes. J Am Coll Surg 2010; 211: 105-13.
21. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol 2007; 165: 262-70.
22. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384: 755-65.
23. Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016; 34: 4225-30.
24. Ju W, Kim HJ, Hankinson SE, De Vivo I, Cho E. Prospective study of body fat distribution and the risk of endometrial cancer. Cancer Epidemiol 2015; 39: 567-70.
25. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015; 350: g7607.
26. Liao C, Zhang D, Mungo C, Andrew Tompkins D, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol 2014; 135: 163-71.
27. Aune D, Sen A, Vatten LJ. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. Sci Rep 2017; 7: 44808.
28. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2014; 20: 748-58.
29. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 2014; 45: 28-36.
30. Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, et al. Reproductive risk factors and endometrial cancer: the European prospective investigation into cancer and nutrition. Int J Cancer 2010; 127: 442-51.
31. Wu QJ, Li YY, Tu C, Zhu J, Qian KQ, Feng TB, et al. Parity and endometrial cancer risk: a meta-analysis of epidemiological studies. Sci Rep 2015; 5: 14243.
32. Yang HP, Cook LS, Weiderpass E, Adami HO, Anderson KE, Cai H, et al. Infertility and incident endometrial cancer risk: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Br J Cancer 2015; 112: 925-33.
33. Gong TT, Wang YL, Ma XX. Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies. Sci Rep 2015; 5: 14051.
34. Yang HP, Murphy KR, Pfeiffer RM, George N, Garcia-Closas M, Lissowska J, et al. Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women. Am J Epidemiol 2016; 183: 800-14.
35. Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, et al. Breastfeeding and endometrial cancer risk: an analysis from the epidemiology of endometrial cancer consortium. Obstet Gynecol 2017; 129: 1059-67.
36. Zhan B, Liu X, Li F, Zhang D. Breastfeeding and the incidence of endometrial cancer: a meta-analysis. Oncotarget 2015; 6: 38398-409.
37. Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer 2015; 136: E410-22.
38. Beining RM, Dennis LK, Smith EM, Dokras A. Meta-analysis of intrauter-ine device use and risk of endometrial cancer. Ann Epidemiol 2008; 18: 492-9.
39. Beral V, Bull D, Reeves G, Million Women Study C. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543-51.
40. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28: 788-92.
41. Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 475-83.
42. Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, et al. Continuous combined estrogen plus progestin and endometrial cancer: the Women's Health Initiative Randomized Trial. J Natl Cancer Inst 2016; 108.
43. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2013; 132: 417-26.
44. Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 2013; 129: 277-84.
45. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013; 381: 1827-34.
46. Yang HP, Brinton LA, Platz EA, Lissowska J, Lacey JV Jr, Sherman ME, et al. Active and passive cigarette smoking and the risk of endometrial cancer in Poland. Eur J Cancer 2010; 46: 690-6.
47. Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 2008; 121: 501-8e3.
48. Moore SC, Gierach GL, Schatzkin A, Matthews CE. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer 2010; 103: 933-8.
49. Schmid D, Behrens G, Keimling M, Jochem C, Ricci C, Leitzmann M. A systematic review and meta-analysis of physical activity and endometrial cancer risk. Eur J Epidemiol 2015; 30: 397-412.
50. Keum N, Ju W, Lee DH, Ding EL, Hsieh CC, Goodman JE, et al. Leisure-time physical activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2014; 135: 682-94.
51. Biel RK, Csizmadi I, Cook LS, Courneya KS, Magliocco AM, Friedenreich CM. Risk of endometrial cancer in relation to individual nutrients from diet and supplements. Public Health Nutr 2011; 14: 1948-60.
52. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Fruits and vegetables and endometrial cancer risk: a systematic literature review and meta-analysis. Nutr Cancer 2007; 58: 6-21.
53. Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 2007; 99: 1534-43.
54. Zhao J, Lyu C, Gao J, Du L, Shan B, Zhang H, et al. Dietary fat intake and endometrial cancer risk: a dose response meta-analysis. Medicine (Baltimore) 2016; 95: e4121.
55. Li X, Zhao J, Li P, Gao Y. Dairy products intake and endometrial cancer risk: a meta-analysis of observational studies. Nutrients 2017; 10.
56. Lafranconi A, Micek A, Galvano F, Rossetti S, Del Pup L, Berretta M, et al. Coffee decreases the risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. Nutrients 2017; 9.
57. Zhou Q, Li H, Zhou JG, Ma Y, Wu T, Ma H. Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 2016; 293: 143-55.
58. Zhou Q, Guo P, Li H, Chen XD. Does alcohol consumption modify the risk of endometrial cancer? A dose-response meta-analysis of prospective studies. Arch Gynecol Obstet 2017; 295: 467-79.
59. Tang YL, Zhu LY, Li Y, Yu J, Wang J, Zeng XX, et al. Metformin use is associated with reduced incidence and improved survival of endometrial cancer: a meta-analysis. BioMed Res Int 2017; 2017: 5905384.
60. Verdoodt F, Friis S, Dehlendorff C, Albieri V, Kjaer SK. Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: a systematic review and meta-analysis of observational studies. Gynecol Oncol 2016; 140: 352-8.
61. Weiderpass E, Pukkala E, Vasama-Neuvonen K, Kauppinen T, Vainio H, Paakkulainen H, et al. Occupational exposures and cancers of the endo-metrium and cervix uteri in Finland. Am J Ind Med 2001; 39: 572-80.
62. Wernli KJ, Ray RM, Gao DL, Fitzgibbons ED, Camp JE, Astrakianakis G, et al. Occupational risk factors for endometrial cancer among textile workers in Shanghai, China. Am J Ind Med 2008; 51: 673-9.
63. Karageorgi S, Gates MA, Hankinson SE, De Vivo I. Perineal use of talcum powder and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2010; 19: 1269-75.
64. Neill AS, Nagle CM, Spurdle AB, Webb PM. Use of talcum powder and endometrial cancer risk. Cancer Causes Control 2012; 23: 513-9.
65. Crawford L, Reeves KW, Luisi N, Balasubramanian R, Sturgeon SR. Perineal powder use and risk of endometrial cancer in postmenopausal women. Cancer Causes Control 2012; 23: 1673-80.
66. Fortuny J, Sima C, Bayuga S, Wilcox H, Pulick K, Faulkner S, et al. Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 2009; 18: 1448-56.
67. Poole EM, Lin WT, Kvaskoff M, De Vivo I, Terry KL, Missmer SA. Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses. Cancer Causes Control 2017; 28: 437-45.
68. Morimoto LM, Newcomb PA, Hampton JM, Trentham-Dietz A. Chole-cystectomy and endometrial cancer: a marker of long-term elevated estrogen exposure? Int J Gynecol Cancer 2006; 16: 1348-53.
69. Lin CF, Chan HL, Hsieh YH, Liang HY, Chiu WC, Huang KY, et al. Endometrial cancer and antidepressants: a nationwide population-based study. Medicine 2016; 95: e4178.
70. Sperling CD, Verdoodt F, Friis S, Dehlendorff C, Kjaer SK. Statin use and riskofendometrial cancer: anationwide registry-based case-control study. Acta Obstet Gynecol Scand 2017; 96: 144-9.
71. Ding YY, Yao P, Verma S, Han ZK, Hong T, Zhu YQ, et al. Use of acetaminophen and risk of endometrial cancer: evidence from observational studies. Oncotarget 2017; 8: 34643-51.
72. Weiderpass E, Adami HO, Baron JA, Wicklund-Glynn A, Aune M, Atuma S, et al. Organochlorines and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9: 487-93.
73. Winer I, Lehman A, Wactawski-Wende J, Robinson R, Simon M, Cote M. Tubal ligation and risk of endometrial cancer: findings from the Women's Health Initiative. Int J Gynecol Cancer 2016; 26: 464-71.
74. Abel EL, Hendrix SL, McNeeley GS, O'Leary ES, Mossavar-Rahmani Y, Johnson SR, et al. Use of electric blankets and association with prevalence of endometrial cancer. Eur J Cancer Prev 2007; 16: 243-50.
75. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol 2015; 125: 89-98.
76. Johnatty SE, Tan YY, Buchanan DD, Bowman M, Walters RJ, Obermair A, et al. Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecol Oncol 2017; 147: 381-7.
77. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 2013; 34: 490-7.
78. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305: 2304-10.
79. Ramsoekh D, Wagner A, van Leerdam ME, Dooijes D, Tops CM, Steyerberg EW, et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract 2009; 7: 17.
80. ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Velthuizen ME, Bernstein I, et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol 2015; 33: 319-25.
81. Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011; 12: 49-55.
82. Sijmons RH, Hofstra RM. Review: clinical aspects of hereditary DNA mismatch repair gene mutations. DNA Repair 2016; 38: 155-62.
83. O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, et al. Identification of nine new susceptibility loci for endometrial cancer. Nat Comm 2018; 9: 3166.
84. Chen MM, Crous-Bou M, Setiawan VW, Prescott J, Olson SH, Wentzensen N, et al. Exome-wide association study of endometrial cancer in a multiethnic population. PLoS One 2014; 9: e97045.
85. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 2008; 8: 1159-67.
86. Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O'Mara T, et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature genetics 2011; 43: 451-4.
87. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013; 31: 2607-18.
88. Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, Berman ML, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997; 10: 963-8.
89. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control 2010; 21: 1851-6.
90. Yang HP, Wentzensen N, Trabert B, Gierach GL, Felix AS, Gunter MJ, et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am J Epidemiol 2013; 177: 142-51.
91. Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME, Brinton LA. Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev 2015; 24: 261-7.
92. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
93. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008; 15: 485-97.
94. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004; 108: 425-32.
95. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001; 84: 975-81.
96. Brinton LA, Trabert B, Anderson GL, Falk RT, Felix AS, Fuhrman BJ, et al. Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2016; 25: 1081-9.
97. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88: 1127-35.
98. Clendenen TV, Hertzmark K, Koenig KL, Lundin E, Rinaldi S, Johnson T, et al. Premenopausal circulating androgens and risk of endometrial cancer: results of a prospective study. Horm Cancer 2016; 7: 178-87.
99. Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez FR. Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur J Cancer 2015; 51: 2747-58.
100. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 921-9.
101. Zhan Y, Wang J, Ma Y, Liu Z, Xu H, Lu S, et al. Serum insulin-like, growth factor binding protein-related protein 1 (IGFBP-rP1) and endometrial cancer risk in Chinese women. Int J Cancer 2013; 132: 411-6.
102. Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, et al. Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Int J Cancer 2017; 140: 600-10.
103. Gong TT, Wu QJ, Wang YL, Ma XX. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: evidence from a meta-analysis of epidemiologic studies. Int J Cancer 2015; 137: 1967-78.
104. Pfeiffer RM, Park Y, Kreimer AR, Lacey JV Jr, Pee D, Greenlee RT, et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med 2013; 10: e1001492.
105. Husing A, Dossus L, Ferrari P, Tjonneland A, Hansen L, Fagherazzi G, et al. An epidemiological model for prediction of endometrial cancer risk in Europe. Eur J Epidemiol 2016; 31: 51-60.
106. Fortner RT, Husing A, Kuhn T, Konar M, Overvad K, Tjonneland A, et al. Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort. Int J Cancer 2017; 140: 1317-23.
107. Sheikh MA, Althouse AD, Freese KE, Soisson S, Edwards RP, Welburn S, et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncol 2014; 10: 2561-8.
108. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adultsinthe United States, 1988-2012. JAMA 2015; 314: 1021-9.
109. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34: 216-9.
110. Curtin SC, Abma JC, Ventura SJ, Henshaw SK. Pregnancy rates for U.S. women continue to drop. NCHS Data Brief 2013: 1-8.
111. Jamal A, Agaku I, O'Connor E, King B, Kenemer J, Neff L. Current cigarette smoking among adults-United States, 2005-2013. MMWR Morb Mortal Wkly Rep 2014; 63: 1108-12.
112. Wright JD, Herzog TJ, Tsui J, Ananth CV, Lewin SN, Lu YS, et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 2013; 122(2 Pt 1): 233-41.
113. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst 2017; 109.
114. Anveden A, Taube M, Peltonen M, Jacobson P, Andersson-Assarsson JC, Sjoholm K, et al. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecol Oncol 2017; 145: 224-9.
115. Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endo-metrial cancer in women with Lynch syndrome. Cancer Prev Res 2013; 6: 774-81.
116. Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 2011; 12: 38-48.
117. Sonoda Y, Barakat RR. Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2006; 20: 363-77.
118. Martinez-Garcia E, Lopez-Gil C, Campoy I, Vallve J, Coll E, Cabrera S, et al. Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Rev Proteomics 2018; 15: 81-99.